Drug intelligence / Profile preview

NP031

Development stage: Discontinued
Lead developer: Noscira
Modality: Small Molecules
Administration: Oral

Overview

**NP031** is a small molecule investigational drug developed as a **phosphodiesterase 4B (PDE4B) isoform inhibitor**. It was studied for potential treatment of **central nervous system (CNS) disorders**, particularly **Alzheimer's disease** and other neurodegenerative conditions, as well as **inflammatory** and **autoimmune diseases**. The drug modulates PDE4B to increase cAMP levels, aiming to improve cognitive function and reduce neuroinflammation, though clinical development appears to have been discontinued following negative trial outcomes.

Targets

GSK3 (Glycogen synthase kinase 3 beta)

Beyond the preview

Go deeper on NP031.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NP031.

Explore the full profile